Feed ELOX
EL

Eloxx Pharmaceuticals, Inc.

ELOX · NASDAQ

$17.45 -8.06% (-$1.53)
1M -2.72%
Market Cap $314.0
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9
Valuation
-
N/A
P/E N/A
PEG N/A
EV/EBITDA N/A
Growth
-
N/A
EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor
ROIC 1,263.55%
Asset turnover 0.00x
ROA 170.74%
Debt
56 /100
Moderate
Current ratio 0.87x
Net debt/EBITDA 0.18x
Int. coverage -16.64x
Stability
44 /100
Moderate
Beta -9.95x
Profitable years 0
EPS volatility 34.31%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ELOX
Online

About the company

Eloxx Pharmaceuticals, Inc. (ELOX) is a biotechnology company specializing in the development of therapeutic therapies for genetic diseases and rare conditions. The company focuses on developing drug products that can correct genetic mutations and provide treatment for patients suffering from genetic disorders. Eloxx Pharmaceuticals targets the treatment of rare diseases such as cystic fibrosis, Duchenne muscular dystrophy, and other genetic disorders. With the growing awareness of the need for genetic disease treatment, Eloxx Pharmaceuticals, Inc. has the potential for sustained growth. Eloxx Pharmaceuticals, Inc. (ELOX) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for genetic diseases.

Sector

Healthcare

Industry

Biotechnology

CEO

Sumit Aggarwal

Employees

10

Headquarters

Watertown

Upcoming events

11 NOV

Earnings

Upcoming earnings report

53d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.